AzTrials
AzTrials

Infant DevelopmentDIMPLENCT06107933

Developmental Impacts of Microplastics Exposure in Early Life

An observational study of Infant Development and Breast Feeding, run by Johns Hopkins Bloomberg School of Public Health at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to characterize and evaluate micro- and nano-plastic (MNP) exposures among mothers and infants in mother-infant dyads 1 or 3 months postpartum living in Baltimore, Maryland. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
What is being tested?
Observational only
How many people
40 participants
Where
1 siteUnited States
Study dates
1 Oct 2023to 1 Jan 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study will include 20 mother-infant pairs from Baltimore City and County. We will be studying lactating mothers at 1 or 3 months postpartum ±2 weeks.

Who may be able to join

  • All gender expressions
  • Mothers at 1 or 3 months postpartum (± 2 weeks)
  • Intent to exclusively breastfeed for ≥ 6 months
  • Nulliparous and singleton births
  • Receiving only breast milk from the mother, with no formula supplementation

Who cannot join

  • Physical, mental, or cognitive disability that prevents participation; current incarceration
  • Chronic conditions in mother and/or infant (e.g., heart disease, cancer, autoimmune disease, diabetes, intestinal bowel syndrome/disease), conditions diagnosed for the first time during pregnancy (e.g. gestational diabetes), neurological conditions in mother and/or infant (e.g. epilepsy, seizures), psychological conditions in mother and/or infant (e.g. bipolar disorder), or neurological/psychological conditions diagnosed in mother during or immediately after pregnancy (e.g. postpartum depression)
  • Previously diagnosed with any major illness (e.g., intrauterine growth restriction, birth asphyxia, cancer) or eating disorder or previous gastric band surgery
  • Maternal antibiotic use during pregnancy or the postpartum period. Infant antibiotic use at any time during life or taking medications that could affect plastic exposure or the microbiome, such as medications administered via a plastic syringe.
  • Use of any breast pump except the Silicon Breast Pump for the 14 days prior to the clinical visit.
  • PHQ9 score greater than or equal to 10 indicating clinically relevant symptoms of moderate or worse depression
  • Infants who are intersex
  • Smoking, drug use (including marijuana use), or alcohol abuse

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Tanya L Alderete, PhD contact

303-735-6249

tanya.alderete@colorado.edu

Charlotte Haslett contact

7813256585

chha5255@colorado.edu

United States1 site, 1 recruiting
  • East Baltimore Pediatric Inpatient and Outpatient Clinical Research Unit

    Baltimore, Maryland, 21287

    Rachel Salamone, RN, 410-614-6365, rsalamo3@jhu.edu

    Recruiting

Other trials in United States

About this study

Official title: Developmental Impacts of MicroPLastics Exposure in Early Life

The goal of this observational study is to characterize and evaluate micro- and nano-plastic (MNP) exposures among mothers and infants in mother-infant dyads 1 or 3 months postpartum living in Baltimore, Maryland. The main questions it aims to answer are:

  • What MNPs are present in breastmilk and maternal blood samples and in their infants stool sample?
  • Are there associations between amount of maternal MNPs in breast milk and mass of MNP particles in infant stool?
  • Which environmental and lifestyle factors are most predictive of maternal MNP burden?
  • Is infant exposure to MNPs associated with birth weight and postnatal growth trajectories?
Read more

Participants will:

  • Complete several questionnaires assessing medical histories, lifestyle factors, environmental exposures, eating behaviors, etc.
  • Provide biological specimens including: maternal blood, stool, and breastmilk; infant stool
  • Clinical visit to have anthropometric measures documented including maternal height and weight, infant weight, length, and skin-fold thickness
Read the detailed description

The proposed pilot study will establish a new cohort of healthy, lactating women from Baltimore City and Baltimore County, Maryland. By recruiting women from these two regions, the investigators will be able to ensure that the pilot study covers a diverse geographical range with varying levels of air pollution exposure and social determinants of health (SDoH). Study participants will be 1 or 3 months postpartum (+/- 2 weeks) and report exclusive breastfeeding. The investigators will also biobank maternal stool samples for future funding applications that will additionally examine the gut microbiome and fecal metabolome.

Height, Weight, Blood Pressure, and other Anthropometric Measures: Maternal height and weight will be measured using a calibrated medical scale and a commercial stadiometer. Infant weight will be measured in duplicate on a digital scale accurate to the nearest 10 g and length will be measured in duplicate to the nearest 0.1 cm using an Infantometer and the standardized World Health Organization (WHO) approach. Infant skinfold thickness will be measured at four sites with Holtain skinfold callipers. Maternal weight will be recorded to the nearest 0.1 kg and height will be recorded to the nearest 0.1 cm. Automated blood pressure using appropriate cuffs will be used to obtain three readings of blood pressure, from which the average value will be recorded, per recommendations of the American Heart Association.

Assessment of Food Intake; Physical Activity: Dietary data will be collected using the National Cancer Institute (NCI) National Health and Nutritional Examination Survey (NHANES) Food Frequency Questionnaire. The questionnaire is designed to capture information about food intake over the prior month, and includes questions outlining consumption of fruits, vegetables, dairy products, whole grain and fiber, sugar, and red and processed meats. The questionnaire will be administered on the web with a research assistant nearby to assist with any questions. Given the investigators are interested in microplastics exposure from food, additional dietary data will be collected through the administration of Nutrition Data System for Research (NDSR) 24-hour dietary recalls which will be administered over the phone by a registered dietician or study staff under the direct supervision of a registered dietician. The investigators will ask mothers to complete 3 dietary recalls for themselves and 3 for their infant, for ideally 2 weekdays and a weekend. One dietary recall for both mother and infant will be completed during the Clinical Visit at the Clinical Research Unit (CRU). Research assistants will work together with participants to establish which days are best suited for them to complete subsequent recalls. Finally, to assess the quantity of milk consumed by infants during a single feeding, the investigators will weigh the infants at the study visit before feeding. Then mothers will be asked to breastfeed their infant. Upon completion of feeding, the investigators will re-weigh the infants to roughly capture the amount of milk consumed.

Maternal and Infant Fecal Samples: Fecal collection kits will be given to eligible participants. To avoid plastic contamination, maternal fecal collection kits will include an absorbent pad covering any plastic on the stool collection hat, gloves, a metal spoon, and glass container. For the infant stool collection, mothers will be provided with a diaper, bee's wrap; cloth, and all collection supplies that are free of plastic. The investigators will deliver these collection supplies and instructions to participants prior to their visit so that participants may collect these samples at home. The investigators will ask them to take the samples within 24 hours of the visit time to preserve the microbial composition of the stool samples. The instructions will specify that samples should be stored in the refrigerator until their visit. The investigators will provide a cooler for participants to transport the samples to the CRU. If for any reason, participants were not able to obtain these samples at home, participants will be allowed to collect them during the visit, If collected at the clinical visit, maternal and infant stool samples will be transferred into 3-4 glass vials and stored in a -4°C fridge for 24 hours prior to being stored at -80°C for MNP and gut microbiome sequencing. Fecal collection tubes utilize a fecal preservative, which prevents changes to aerobic and anaerobic bacteria that can occur during shipment. Fecal sequencing will be performed at Emory University (Dr. Doug Walker). Only de-identified samples will be sent to Dr. Walker's lab. DNA will be sequenced on the Illumina HiSeq 4000 platform. Microbial composition profiles will be predicted using MetaPhlan. Samples will be functionally mapped using HUMAnN2 to obtain abundance level of gene families from the UniProt Reference Clusters that will be further mapped to MetaCyc metabolic pathways database. Genes will be grouped in clusters of orthologous groups from EggNOG data. Gene family abundances will be grouped into broader functional categories based on annotation for the UniProt gene ontology. For the metabolomics analysis, fecal samples will be analyzed using ultra-performance liquid chromatography (UPLC) and high resolution/tandem mass spectrometry (MS/MS) by Metabolon. Compounds of exogenous, human, and microbial origin will be identified by comparison to library entries of purified standards or recurrent unknown entities. Metabolon maintains a reference library of more than 4,500 known metabolites and more than 9,000 novel metabolites. Biochemical identifications will be based on three criteria: retention index, accurate mass match to the library +/- 10 ppm, and the MS/MS forward and reverse scores between the experimental data and authentic standards.

Breast Milk Expression: Due to potential exposures from feeding breast milk from plastic bottles, all mothers will be asked to only feed their infants from the breast for 14 days prior to infant stool collection. Similar to the stool collection supplies, the investigators will provide mothers with a Haakaa Silicone Breast Pump, silicone storage container with cap, and instructions prior to the study visit. Mothers will be asked to provide a full expression of a single breast. If mothers are uncomfortable providing a full expression, study coordinators will work with mothers to determine an amount appropriate for collection. The investigators will collect a minimum of roughly 4g of breast milk. If mothers are unable to collect their breastmilk sample before the visit, mothers will be provided with a quiet, private CRU study room to pump using a Haakaa Silicone Breast Pump into a silicone storage container. Following collection, a member of our study team will aliquot measures into glass sterile tubes for storage. Following collection, all samples will be stored at -80 degrees C prior to processing and analysis.

Blood Draw: Blood draws will be collected (40mL) for microplastics analysis. Blood will be collected using a stainless steel 21G needle that is connected to a glass container under vacuum, so blood drawn directly from participant is deposited in the glass vacutainer. Glass vacutainers will have a rubber seal for storage.

Being tested
Observational only
Keywords
microplastic, breastmilk, infant microplastic exposure, gut microbiome, fecal metabolome
Medical subject headings
Breast Feeding

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Observational onlyOther

    Exposure to micro and nano plastics

Study groups in NCT06107933
Study groupRoleWhat they receive
City Mother-Infant PairsMother-infant pairs living in a Baltimore City, Maryland zip code exposed to micro and nano plastics.
Receives: Other: Observational only
County Mother-Infant PairsMother-infant pairs living in a Baltimore County, Maryland zip code exposed to micro and nano plastics.
Receives: Other: Observational only

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Microplastic composition in maternal breastmilk

    MNPs are measured using pyrolysis GC-HRMS using a Frontier Multi-Shot Pyrolyzer with Auto-Shot Sampler interfaced to a Trace 1310 gas chromatography system and Thermo Scientific Q Exactive GC Orbitrap GC-MS/MS.

    Measured: 1 or 3 months +/- 2 weeks postpartum

  2. Microplastic composition in maternal venous blood

    MNPs are measured using pyrolysis GC-HRMS using a Frontier Multi-Shot Pyrolyzer with Auto-Shot Sampler interfaced to a Trace 1310 gas chromatography system and Thermo Scientific Q Exactive GC Orbitrap GC-MS/MS.

    Measured: 1 or 3 months +/- 2 weeks postpartum

  3. Microplastic composition in infant stool

    MNPs are measured using pyrolysis GC-HRMS using a Frontier Multi-Shot Pyrolyzer with Auto-Shot Sampler interfaced to a Trace 1310 gas chromatography system and Thermo Scientific Q Exactive GC Orbitrap GC-MS/MS.

    Measured: 1 or 3 months +/- 2 weeks postpartum

  4. Infant weight

    Infant weight will be measured in duplicate on a digital scale accurate to the nearest 10 g

    Measured: 1 or 3 months +/- 2 weeks postpartum

  5. Infant length

    Infant length will be measured in duplicate to the nearest 0.1 cm using an Infantometer.

    Measured: 1 or 3 months +/- 2 weeks postpartum

  6. Infant skinfold thickness

    Infant skinfold thickness will be measured at four sites with Holtain skinfold callipers

    Measured: 1 or 3 months +/- 2 weeks postpartum

Secondary outcomes (1)
  1. Maternal stool microbiome composition

    Maternal stool will be stored in cryovials at -80C for future metagenomic sequencing to analyze the composition of the gut microbiome.

    Measured: 1 or 3 months +/- 2 weeks postpartum

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2023
  2. Study start1 Oct 2023
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion1 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06107933
Sponsor's protocol ID
IRB00030652
Other IDs
23-0314
Acronym
DIMPLE
Status last verified
Jun 2026
First submitted
3 Oct 2023
Last updated
9 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Geyer R, Jambeck JR, Law KL. Production, use, and fate of all plastics ever made. Sci Adv. 2017 Jul 19;3(7):e1700782. doi: 10.1126/sciadv.1700782. eCollection 2017 Jul.

    PubMed 28776036
  • Veidis EM, LaBeaud AD, Phillips AA, Barry M. Tackling the Ubiquity of Plastic Waste for Human and Planetary Health. Am J Trop Med Hyg. 2021 Nov 8;106(1):12-14. doi: 10.4269/ajtmh.21-0968. No abstract available.

    PubMed 34749307
  • Usman S, Abdull Razis AF, Shaari K, Azmai MNA, Saad MZ, Mat Isa N, Nazarudin MF. The Burden of Microplastics Pollution and Contending Policies and Regulations. Int J Environ Res Public Health. 2022 Jun 1;19(11):6773. doi: 10.3390/ijerph19116773.

    PubMed 35682361
  • Law KL, Starr N, Siegler TR, Jambeck JR, Mallos NJ, Leonard GH. The United States' contribution of plastic waste to land and ocean. Sci Adv. 2020 Oct 30;6(44):eabd0288. doi: 10.1126/sciadv.abd0288. Print 2020 Oct.

    PubMed 33127684
  • Kannan K, Vimalkumar K. A Review of Human Exposure to Microplastics and Insights Into Microplastics as Obesogens. Front Endocrinol (Lausanne). 2021 Aug 18;12:724989. doi: 10.3389/fendo.2021.724989. eCollection 2021.

    PubMed 34484127
  • Sendra M, Pereiro P, Figueras A, Novoa B. An integrative toxicogenomic analysis of plastic additives. J Hazard Mater. 2021 May 5;409:124975. doi: 10.1016/j.jhazmat.2020.124975. Epub 2020 Dec 26.

    PubMed 33388451
  • Rustagi N, Pradhan SK, Singh R. Public health impact of plastics: An overview. Indian J Occup Environ Med. 2011 Sep;15(3):100-3. doi: 10.4103/0019-5278.93198.

    PubMed 22412286
  • Yang H, He Y, Yan Y, Junaid M, Wang J. Characteristics, Toxic Effects, and Analytical Methods of Microplastics in the Atmosphere. Nanomaterials (Basel). 2021 Oct 17;11(10):2747. doi: 10.3390/nano11102747.

    PubMed 34685192
  • Yong CQY, Valiyaveettil S, Tang BL. Toxicity of Microplastics and Nanoplastics in Mammalian Systems. Int J Environ Res Public Health. 2020 Feb 26;17(5):1509. doi: 10.3390/ijerph17051509.

    PubMed 32111046
  • Leslie HA, van Velzen MJM, Brandsma SH, Vethaak AD, Garcia-Vallejo JJ, Lamoree MH. Discovery and quantification of plastic particle pollution in human blood. Environ Int. 2022 May;163:107199. doi: 10.1016/j.envint.2022.107199. Epub 2022 Mar 24.

    PubMed 35367073
  • Luqman A, Nugrahapraja H, Wahyuono RA, et al. Microplastic Contamination in Human Stools, Foods, and Drinking Water Associated with Indonesian Coastal Population. Environments. 2021;8(12):138. doi:10.3390/environments8120138

  • Zhang N, Li YB, He HR, Zhang JF, Ma GS. You are what you eat: Microplastics in the feces of young men living in Beijing. Sci Total Environ. 2021 May 1;767:144345. doi: 10.1016/j.scitotenv.2020.144345. Epub 2020 Dec 31.

    PubMed 33434834
  • Schwabl P, Koppel S, Konigshofer P, Bucsics T, Trauner M, Reiberger T, Liebmann B. Detection of Various Microplastics in Human Stool: A Prospective Case Series. Ann Intern Med. 2019 Oct 1;171(7):453-457. doi: 10.7326/M19-0618. Epub 2019 Sep 3.

    PubMed 31476765
  • Yan Z, Liu Y, Zhang T, Zhang F, Ren H, Zhang Y. Analysis of Microplastics in Human Feces Reveals a Correlation between Fecal Microplastics and Inflammatory Bowel Disease Status. Environ Sci Technol. 2022 Jan 4;56(1):414-421. doi: 10.1021/acs.est.1c03924. Epub 2021 Dec 22.

    PubMed 34935363
  • Liu S, Guo J, Liu X, Yang R, Wang H, Sun Y, Chen B, Dong R. Detection of various microplastics in placentas, meconium, infant feces, breastmilk and infant formula: A pilot prospective study. Sci Total Environ. 2023 Jan 1;854:158699. doi: 10.1016/j.scitotenv.2022.158699. Epub 2022 Sep 13.

    PubMed 36108868

Questions about this trial

What is this clinical trial studying?

An observational study of Infant Development and Breast Feeding, run by Johns Hopkins Bloomberg School of Public Health at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Tanya L Alderete, PhD (303-735-6249, tanya.alderete@colorado.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Microplastic composition in maternal breastmilk (time frame: 1 or 3 months +/- 2 weeks postpartum). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06107933, which also lists 106 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in